On October 22, the official website of the China Drug Administration revealed that Suhuan®, an umeponium bromide inhalation powder independently developed by the core Chinese biopharmaceutical company Zhengda Tianqing, was approved for marketing for long-term maintenance treatment of chronic obstructive pulmonary disease.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.